|
KMID : 1040320230300010047
|
|
Pediatric Infection & Vaccine
2023 Volume.30 No. 1 p.47 ~ p.54
|
|
|
Treatment of Multidrug-resistant Pseudomonas aeruginosa Bacteremia in a Immunocompromised Child With Ceftolozane-tazobactam
|
|
Yu Hye-Sun
Shin A-Reum
Kim Doo-Ri
Choi Jae-Young
Ju Hee-Young
Cho Joong-Bum
Kang Cheol-In
Kim Yae-Jean
|
|
|
Abstract
|
|
|
With the widespread use of broad-spectrum antibiotics in clinical practice, the emergence of multidrug-resistant (MDR) gram-negative bacteria has become a global problem. The MDR Pseudomonas aeruginosa infection is especially difficult to treat and increases mortality in critically ill patients. Ceftolozane-tazobactam (Zerbaxa™) is a fifth-generation cephalosporin and beta-lactamase inhibitor that has proved to be effective for treating complicated urinary tract infections and complicated intra-abdominal infections caused by MDR P. aeruginosa.
Herein, we report the first case of pediatric hematologic cancer in Korea that was successfully treated for MDR P. aeruginosa bacteremia with Ceftolozane-tazobactam.
|
|
|
KEYWORD
|
|
|
Drug resistance, multiple, Pseudomonas aeruginosa
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|